Publication: Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper.
No Thumbnail Available
Identifiers
Date
2018-10-05
Authors
Roth-Walter, Franziska
Adcock, Ian M
Benito-Villalvilla, Cristina
Bianchini, Rodolfo
Bjermer, Leif
Caramori, Gaetano
Cari, Luigi
Chung, Kian Fan
Diamant, Zuzana
Eguiluz-Gracia, Ibon
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley and Sons
Abstract
Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health. Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens. On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact. Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development. SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs. Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.
Description
MeSH Terms
Asthma
Biological Products
Biomarkers
Chronic Disease
Diagnosis, Differential
Disease Management
Humans
Molecular Targeted Therapy
Phenotype
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Treatment Outcome
Biological Products
Biomarkers
Chronic Disease
Diagnosis, Differential
Disease Management
Humans
Molecular Targeted Therapy
Phenotype
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Treatment Outcome
DeCS Terms
Enfermedades Respiratorias
Enfermedad Pulmonar Obstructiva Crónica
Asma
Espacio Aéreo
Salud Pública
Necesidades y Demandas de Servicios de Salud
Enfermedad Pulmonar Obstructiva Crónica
Asma
Espacio Aéreo
Salud Pública
Necesidades y Demandas de Servicios de Salud
CIE Terms
Keywords
Antibodies, Asthma, Biologicals, Chronic obstructive pulmonary disease, Small molecule drugs
Citation
Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Caramori G, et al. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. Allergy. 2019 Mar;74(3):432-448